SCHEMBL8317282

SCHEMBL8317282

O=C(NC1CC1)c1ccccc1-c1cnc2[nH]cc(-c3ccoc3)c2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.59
RIPK1 Q13546 1/20 0.47
IGF1R P08069 1/20 0.46
CCNT1 O60563 1/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CDK9 P50750 1/20 0.46
CAMKK2 Q96RR4 8/20 0.46
ALOX5AP P20292 1/20 0.44
FEN1 P39748 1/20 0.44
SGK1 O00141 2/20 0.44
AURKA O14965 1/20 0.44
CAMKK1 Q8N5S9 1/20 0.44
SGK3 Q96BR1 1/20 0.44
SGK2 Q9HBY8 1/20 0.44
TNIK Q9UKE5 1/20 0.44
GAA P10253 1/20 0.43
AXL P30530 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13745394 0.95 CDK8 (0.56) CDK8RIPK1IGF1RCCNT1CCNA2
SCHEMBL13745546 0.86 CDK8 (0.56) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL8316526 0.85 CDK8 (0.71) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL8314436 0.85 CDK8 (0.59) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL13746026 0.84 CDK8 (0.64) CDK8RIPK1IGF1RCCNT1CCNA2
SCHEMBL8281970 0.84 CDK8 (0.54) CDK8RIPK1IGF1RCCNT1CCNA2
SCHEMBL8318330 0.84 CDK8 (0.58) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL8313356 0.82 CDK8 (0.56) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL8320558 0.82 CDK8 (0.64) CDK8IGF1RCCNT1CCNA2CDK2
SCHEMBL13745336 0.82 CDK8 (0.61) CDK8IGF1RCCNT1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 CDK8 360/4885RIPK1 152/4885IGF1R 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.